Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study
- PMID: 20833412
- PMCID: PMC2975753
- DOI: 10.1016/j.thromres.2010.08.010
Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study
Abstract
Introduction: Because the risk of venous thromboembolism (VTE) associated with progestin is uncertain, we tested oral contraceptives, estrogen and progestin as independent VTE risk factors.
Materials and methods: Using longitudinal, population-based Rochester Epidemiology Project resources, we identified all Olmsted County, MN women with objectively-diagnosed incident VTE over the 13-year period, 1988-2000 (n=726) and one to two Olmsted County women per case matched on age, event year and duration of prior medical history (n=830), and reviewed their complete medical history in the community for previously-identified VTE risk factors (i.e., hospitalization with or without surgery, nursing home confinement, trauma/fracture, leg paresis, active cancer, varicose veins and pregnancy/postpartum), and oral contraceptive, oral estrogen, and oral or injectable progestin exposure. Using conditional logistic regression we tested these hormone exposures as VTE risk factors, both unadjusted and after adjusting for previously-identified VTE risk factors.
Results: In unadjusted models, oral contraceptives, progestin alone, and estrogen plus progestin were significantly associated with VTE. Individually adjusting for body mass index (BMI) and previously-identified VTE risk factors, these effects remained essentially unchanged except that progestin alone was not associated with VTE after adjusting for active cancer. Considering only case-control pairs without active cancer, progestin alone was positively but non-significantly associated with VTE (OR=2.49; p=0.16). Adjusting for BMI and previously-identified VTE risk factors including active cancer, oral contraceptives, estrogen alone, and progestin with or without estrogen were significantly associated with VTE.
Conclusions: Oral contraceptives, estrogen alone, estrogen plus progestin, and progestin with or without estrogen are independent VTE risk factors.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.Thromb Res. 2016 Mar;139:29-37. doi: 10.1016/j.thromres.2016.01.002. Epub 2016 Jan 5. Thromb Res. 2016. PMID: 26916293 Free PMC article.
-
Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study.Thromb Res. 2015 Jun;135(6):1110-6. doi: 10.1016/j.thromres.2015.04.005. Epub 2015 Apr 11. Thromb Res. 2015. PMID: 25891841 Free PMC article.
-
Estrogen and progestin components of oral contraceptives: relationship to vascular disease.Contraception. 1997 May;55(5):267-72. doi: 10.1016/s0010-7824(97)00029-2. Contraception. 1997. PMID: 9220222 Review.
-
Population-based study of risk of venous thromboembolism associated with various oral contraceptives.Lancet. 1997 Jan 11;349(9045):83-8. doi: 10.1016/s0140-6736(96)07496-x. Lancet. 1997. PMID: 8996419
-
Birth Control Pills and Thrombotic Risks: Differences of Contraception Methods with and without Estrogen.Hamostaseologie. 2019 Feb;39(1):42-48. doi: 10.1055/s-0039-1677806. Epub 2019 Jan 22. Hamostaseologie. 2019. PMID: 30669160 Review.
Cited by
-
Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): A Review of Its Use as an Oral Contraceptive.Drugs. 2015 Jun;75(9):1019-26. doi: 10.1007/s40265-015-0407-9. Drugs. 2015. PMID: 26017303 Review.
-
Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals.Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020032. doi: 10.4084/MJHID.2020.032. eCollection 2020. Mediterr J Hematol Infect Dis. 2020. PMID: 32395221 Free PMC article. Review.
-
An Update on Contraception in Polycystic Ovary Syndrome.Endocrinol Metab (Seoul). 2021 Apr;36(2):296-311. doi: 10.3803/EnM.2021.958. Epub 2021 Apr 15. Endocrinol Metab (Seoul). 2021. PMID: 33853290 Free PMC article.
-
Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea: A case report.Medicine (Baltimore). 2019 Jul;98(28):e16318. doi: 10.1097/MD.0000000000016318. Medicine (Baltimore). 2019. PMID: 31305418 Free PMC article.
-
Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.Thromb Res. 2016 Mar;139:29-37. doi: 10.1016/j.thromres.2016.01.002. Epub 2016 Jan 5. Thromb Res. 2016. PMID: 26916293 Free PMC article.
References
-
- Marcelo P, Gomes V, Steven R, Deitcher M. Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy. A Clinical Review. Arch of Internal Medicine(Reprinted 1965–1975) 2004;164:1965–1975. - PubMed
-
- Vasilakis C, Jick S, Jick H. The risk of venous thromboembolism in users of postcoital contraceptive pills. Contraception. 1999;59:79–83. - PubMed
-
- Poulter N, Chang C, Farley T, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet. 1999;354:1610. - PubMed
-
- Jick H, Jick S, Gurewich V, Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593. - PubMed
-
- Daly E, Vessey M, Hawkins M, Carson J, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977–980. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources